Pemigatinib’s job is to keep theFGFR signaling in check. It’s used to help treat cholangiocarcinoma when there’s an FGFR2 fusion in the mix. The drug tablets come in three different strengths: 4.5 mg, 9 mg, and 13.5 mg.
For adults, doctors usually recommend taking the 13.5 mg tablet every day. Treatment is administered over a 14-day cycle within a 21-day cycle, with a total of 14 tablets per bottle. The way they give you the drug is to specifically target the FGFR pathway, which tends to be out of whack in FGFR2 fusion cancers.
This can help slow down the cancer growth and make things better for patients.
Reviews
There are no reviews yet.